What perimenopause means for your health 10-20 years from now — and what the evidence shows about prevention and monitoring.
A 1-minute view of what this section covers. Tap any item to read the full discussion.
Different endpoints follow different trajectories. Aortic stiffness acceleration emerged only 8+ years after the final menstrual period, not during the transition itself.
Read full discussion →In 919,614 women, transdermal unopposed estrogen showed no significant CV/VTE associations, but transdermal estrogen as part of combined therapy had VTE HR 1.46-1.67. Route, progestogen, and endpoint must be separated.
Read full discussion →Hormone therapy reduces fracture risk regardless of fall risk or baseline FRAX. Both oral and transdermal provide similar skeletal benefits. Non-hormonal VMS treatments do not provide bone protection.
Read full discussion →A systematic review of 43 studies found no consistent benefit. Only 1 of 15 RCTs used micronized progesterone — the rest used older, more androgenic progestins that differ from current practice.
Read full discussion →The menopausal transition is not just a symptom phase — it is a period when cardiovascular, metabolic, and bone health trajectories shift. Understanding these shifts matters because risk factors and treatment decisions discussed during the transition may shape health over the next 10-20 years.
Cardiovascular risk during and after menopause is best understood as three distinct timing layers — not collapsed into "menopause causes heart disease."
Layer 1 — Lipid and lipoprotein burden shifts during perimenopause. In the SWAN cohort, LDL-C, ApoB, and total LDL particle counts all increased significantly during the perimenopause stage. ApoB and total LDL-P were independently associated with subclinical atherosclerosis measures (carotid intima-media thickness, coronary artery calcium). These are surrogate endpoints — they measure artery-wall changes, not heart attacks or strokes (25).
Layer 2 — Palpitations co-occur with the transition but are not independently linked to subclinical cardiovascular disease. About half of women experience moderate-to-high palpitations during perimenopause and early postmenopause (trajectories: sustained low 49.8%, moderate 34.3%, high 15.9%). In fully adjusted SWAN models, palpitation trajectories were not associated with subclinical CVD markers after accounting for BMI, blood pressure, glucose, and sleep (13). Chest pain, syncope, or persistent new arrhythmia fall outside this reassuring pattern and are appropriately evaluated in a clinical setting.
Layer 3 — Aortic stiffness acceleration is a late-postmenopause phenomenon. Significant carotid-femoral pulse wave velocity acceleration (0.122 m/s per year, p<0.001) emerged in late postmenopause (8 or more years after the final menstrual period) — not during the transition itself. The clinical implication: the risk-factor deterioration that happens around the transition (lipids, adiposity, blood pressure) is what later contributes to measured arterial changes (30).
CVD is the leading cause of death in women worldwide — causing approximately 10 times more deaths than breast cancer in the US. At the same time, guideline consensus is clear that estrogen is not recommended solely for primary cardiovascular prevention despite favorable effects on some risk factors (53).
"Is hormone therapy safe for my heart?" does not have a single answer. The evidence shows that formulation, route, regimen, and the specific cardiovascular outcome measured all change the picture.
A Korean nationwide cohort found adjusted higher composite CVD risk for tibolone (HR 1.14), oral estrogen (HR 1.25), and transdermal estrogen (HR 1.29) — though crude event incidence was actually lower among HT users (5.5% vs 7.4%), with the adjusted risk emerging only after accounting for confounding (36). The Swedish and Korean studies do not fully agree on transdermal-estrogen cardiovascular risk — this is cross-study heterogeneity, not a settled answer.
When a woman carries multiple conditions that affect route choice, the decision involves balancing competing considerations rather than following a single rule:
Dyslipidemia axis: produce stronger LDL/Lp(a) reductions and HDL increases, but may raise triglycerides. Per an EMAS clinical guide, an is preferred when hypertriglyceridemia is present. Lp(a) reduction with MHT was 20.4%, with oral producing a 37.7% greater relative reduction than transdermal (8). MHT is not a first-line therapy for dyslipidemia or cardiovascular risk reduction — statins remain the mainstay.
Type 2 diabetes / glucose axis: showed advantages for glucose metabolism in women with T2D at low cardiovascular risk. Transdermal is preferred when moderate-to-high cardiovascular risk or obesity dominates. This is the opposite direction from the general cardiovascular route preference (33).
Vascular / migraine / VTE axis: Reviewed guidance generally favors low-dose transdermal estrogen for women with migraine (especially with aura), hypertension, BMI ≥30, or prior VTE/stroke risk.
Across all three axes, in the reviewed evidence, micronized progesterone and dydrogesterone tend to have lower-risk profiles (neutral on lipids, neutral on glucose, lower breast-cancer and meningioma signals than several synthetic progestins in the cited studies). This framework is a balancing tool, not a hierarchy — clinicians weigh which comorbidity dominates the individual patient's risk profile.
Body composition and lipid parameters worsen during perimenopause but stabilize after menopause, shifting to a slower age-related trajectory (53). In the US, 74.2% of midlife women were overweight or obese in 2021 (up from 49.2% in 1990), with projections reaching 83.4% by 2050. The increase is driven by a shift into the obesity-range BMI category, not simply stable overweight prevalence (119).
Lean and muscle mass decline across the transition. SWAN longitudinal data show the annual rate of lean-mass decline accelerates during the transition (-0.68% per year) compared to pre-FMP years (-0.17%) and stabilizes afterward (+0.02%). Most evidence uses DXA, which overestimates muscle mass compared to direct measures like MRI or CT. The human evidence linking estradiol decline specifically to muscle protein breakdown remains speculative — it is supported by animal and cell models only. Resistance exercise remains the practical intervention with evidence that postmenopausal women still gain lean mass with training despite potentially blunted responses (115).
Hormone therapy is not established for sarcopenia prevention. A systematic review of 43 studies found no consistent benefit, and critically, only 1 of 15 included RCTs used micronized progesterone — the rest used older, more androgenic progestins. Modern regimens (transdermal estradiol plus micronized progesterone) are essentially unstudied for this outcome (68).
[EVIDENCE] In the first two years after the final menstrual period, women lose approximately 2.5% of lumbar spine bone density per year and 1.8% of femoral neck density per year (SWAN longitudinal data). Hormone therapy reduces fracture risk regardless of fall risk or baseline FRAX score. Both oral and transdermal routes provide similar skeletal benefits, with some evidence that estradiol may be slightly more effective than conjugated equine estrogen. Benefits persist during therapy and may continue after stopping. Non-hormonal VMS treatments do not provide bone protection. (PMID 39928407, ref 53)
Emerging screening research suggests site-specific predictors: FSH independently predicts lumbar spine BMD (β=-0.072, p=0.009), while estradiol predicts femoral neck BMD (β=0.138, p=0.020) — different hormones, different bones. A combined β-CTX and low-estradiol screening approach achieved an AUC of 0.950 for identifying high-risk perimenopausal women (100, 103). Both thresholds are observed and not yet prospectively validated.
Elinzanetant showed no clinically meaningful BMD or bone-turnover changes versus placebo over 52 weeks in OASIS-3 — an elinzanetant-specific finding that does not generalize to the whole NK antagonist class or to longer-term use (83).
POI and early menopause carry distinct long-term cardiovascular and metabolic risk patterns — including a 50% increased risk of type 2 diabetes and premature mortality driven largely by CVD from estrogen deficiency. Asian women may face disproportionately higher cardiovascular risk at lower BMI. These patterns and their management are covered in the Special Populations section (60).